In late July, the first recall in the new regulatory environment was issued and days later, a different company issued another recall.
In Part 4, Dr. Askew explains matrix spikes and duplicate QC analyses for those looking to vet their lab partners
The UK moves to reschedule cannabis as a Schedule II drug.
A2LA and EVIO Inc. announced the accreditation yesterday ahead of the state’s upcoming recreational implementation.
Smyth sat in a session on budtender training at last week’s NCIA Cannabis Business Summit and offers her summary of the events.
Six days after Cannabis Industry Journal reported that the old “witch” was dead, BfArM issued the new cannabis bid.
The NCIA is releasing white papers this week with recommendations for cannabis testing policy and guidance for businesses dealing with crisis communications.
Restricted from market entry by regulation, evidence-based procedures and barred from advertising, how should cannabis companies conquer European market entry? Trials are one smart way in the immediate future.
While the USPTO might not register your trademark, there are still some tools available to protect your intellectual property.
In Part 3, Dr. Askew dissects quality control results from labs and how a client could better understand them.
